Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.~2. Must be 6 to less than 18 years of age at the time of randomization~3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.~4. Subject being regarded by the investigator to be a candidate for systemic therapy.~Exclusion Criteria:~1. Forms of psoriasis other than chronic plaque-type active at randomization~2. Drug-induced psoriasis~3. Ongoing use of prohibited treatments~4. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment~5. Pregnant or nursing (lactating) females~6. Subjects with total WBC count \<2,500/μL, or platelets \<100,000/μL or neutrophils \<1,500/μL or hemoglobin \<8.5 g/dL at screening~7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- secukinumab low dose (Type: EXPERIMENTAL): secukinumab low dose
- secukinumab high dose (Type: EXPERIMENTAL): secukinumab high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).